MONJUVI (tafasitamab-cxix) is a prescription medicine given with lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory) and who cannot receive a stem cell transplant.
It is not known if MONJUVI is safe and effective in children.
The approval of MONJUVI is based on a type of response rate. There is an ongoing study to confirm the clinical benefit of MONJUVI.
What to expect from treatment with MONJUVI
You and your healthcare team may be considering whether to begin your treatment with MONJUVI. Or, you may be seeking more information about MONJUVI for yourself or a loved one.
This website provides important information about what to expect during treatment with MONJUVI. It includes details about how treatment may help you, how you can receive MONJUVI, the side effects you may experience, and support options for you during your treatment.
Learn about how MONJUVI was studied and see the results from a clinical trial.